The
biotech company has developed a groundbreaking gene therapy for treating rare genetic disorders.
生物科技公司开发出了一种突破性的基因疗法，用于治疗罕见遗传病。
Biotech researchers are harnessing CRISPR technology to edit the DNA of crops, enhancing their yield and resilience to pests.
生物科技研究人员正在利用CRISPR技术编辑农作物的DNA，以提高其产量和抗虫能力。
The
biotech industry is rapidly expanding, fueled by advancements in immunotherapy and personalized medicine.
在免疫疗法和个性化药物发展的推动下，生物科技行业正迅速扩张。
The
biotech startup secured a significant round of funding to accelerate the clinical trials of its novel cancer vaccine.
这家生物科技初创公司获得了大量资金支持，以加快其新型癌症疫苗的临床试验进程。
By utilizing
biotech methods, scientists have successfully produced insulin from genetically engineered bacteria, revolutionizing diabetes treatment.
科学家通过运用生物科技方法，成功地从基因工程改造的细菌中生产出胰岛素，彻底改变了糖尿病的治疗方法。
Biotech firms are exploring the use of microorganisms to remediate contaminated soil and water, promoting environmental sustainability.
生物科技公司正在探索利用微生物来修复受污染的土壤和水体，以促进环境可持续性。
The new
biotech campus will serve as a hub for interdisciplinary collaboration, fostering innovation in areas such as synthetic biology and regenerative medicine.
新建的生物科技园区将成为跨学科合作的中心，推动合成生物学和再生医学等领域创新。
With the advent of
biotech, farmers can now utilize biopesticides derived from natural substances, reducing reliance on synthetic chemicals.
随着生物科技的发展，农民现在可以使用源自天然物质的生物农药，从而减少对合成化学物质的依赖。
The
biotech conference brought together leading experts to discuss emerging trends in genome editing and its ethical implications.
这次生物科技会议汇聚了各领域专家，共同探讨基因编辑的新兴趋势及其伦理影响。
The government is investing heavily in
biotech research to boost the nation's competitiveness in the global healthcare market.
政府正在大力投资生物科技研究，以提升该国在全球医疗保健市场的竞争力。
In March, Shanghai Junshi Biosciences Co Ltd announced collaboration with Singapore-based Rxilient Biotech on development and commercialization of an antibody drug through a joint venture in nine Southeast Asian nations — Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines and Vietnam.
今年3月，上海君实生物科技有限公司宣布，通过在泰国、文莱、柬埔寨、印度尼西亚、老挝、马来西亚、缅甸、菲律宾和越南等九个东南亚国家的合资企业，与新加坡的Rxilent Biotech合作开发抗体药物并将其商业化。
American biotech company Moderna on Monday commenced construction on its first pharmaceutical plant in China, with an estimated investment of 3.6 billion yuan ($501 million).
上海——周一，美国生物技术公司莫德纳开始在中国建设第一家制药厂，预计投资36亿元人民币（5.01亿美元）。
In an online media conference on Monday, Yao Sheng, senior vice-president of Junshi Biosciences, said the company had signed cooperation agreements with foreign partners including Coherus, Hikma, Rxilient Biotech and Dr. Reddy's that cover more than 50 markets, and expects the drug to get greater presence worldwide following the approval from the US FDA.
在周一的一次在线媒体会议上，君实生物高级副总裁姚胜表示，该公司已与包括Cohereus、Hikma、Rxilient Biotech和Dr.Reddy’s在内的外国合作伙伴签署了涵盖50多个市场的合作协议，并预计该药物在获得美国食品药品监督管理局批准后将在全球范围内获得更大的影响力。
The Chinese biotech and its US partner Coherus BioSciences Inc jointly announced on Oct 27 that the US FDA approved Loqtorzi (toripalimab-tpzi) in combination with other drugs for the first-line treatment of adults with metastatic or recurrent locally advanced metastatic nasopharyngeal carcinoma (NPC), and as monotherapy for the treatment of adults with recurrent, or metastatic NPC with disease progression on or after platinum-containing chemotherapy.
10月27日，中国生物技术公司及其美国合作伙伴Cohereus BioSciences Inc联合宣布，美国FDA批准Loqtorzi（托帕利单抗-tpzi）与其他药物联合用于成人转移性或复发性局部晚期转移性鼻咽癌（NPC）的一线治疗，或在含铂化疗时或之后具有疾病进展的转移性NPC。
Since late 2018, a group of Chinese biotech companies have joined a global team of organizations who have come up with homegrown PD-1/PD-L1 inhibitors.
自2018年底以来，一群中国生物技术公司加入了一个全球组织团队，他们开发了国产PD-1/PD-L1抑制剂。
Collaboration programs initiated by United States-based biotech company Amgen at last year's China International Import Expo are continuing to bear fruit and benefit Chinese patients, said the company's top China executive during an interview with China Daily on Monday.
总部位于美国的生物技术公司安进在去年的中国国际进口博览会上发起的合作项目正在继续取得成果，并使中国患者受益，该公司中国区首席执行官周一在接受《中国日报》采访时表示。
Riding BRI, vaccine giant seeks more cooperation with overseas partnersChinese vaccine company Sinovac Biotech is in talks with potential partners to localize the production of its vaccines in more foreign countries, said its executives.
借助“一带一路”倡议，疫苗巨头寻求与海外合作伙伴开展更多合作。中国疫苗公司科兴生物技术有限公司高管表示，该公司正在与潜在合作伙伴进行谈判，以将其疫苗生产本地化到更多外国。
A more important role that Chinese biotech companies like Sinovac could play is cooperating with foreign partners to localize the production of Chinese vaccines rather than exporting the products.
像科兴这样的中国生物技术公司可以发挥的一个更重要的作用是与外国合作伙伴合作，将中国疫苗的生产本地化，而不是出口产品。
Digitization, green transition, biotech, new consumption key growth driversChina was the best performer in Temasek's global portfolio over the past decade, as the country's continuous opening-up agenda provided foreign investors with solid opportunities, the head of the Singapore-based investment company in China said on Thursday.
数字化、绿色转型、生物技术、新消费是关键的增长驱动力这家总部位于新加坡的投资公司的负责人周四表示，过去十年，中国是淡马锡全球投资组合中表现最好的，因为该国持续的开放议程为外国投资者提供了坚实的机会。
Upbeat about such areas as digitization, green transition, biotech and new consumption patterns, Temasek's investments in China have outnumbered divestments over the past year as of end-March, resulting in a net investment, Wu said.
吴表示，在数字化、绿色转型、生物技术和新消费模式等领域，淡马锡在中国的投资在过去一年中，截至3月底，已超过撤资，因此产生了净投资。
According to US industrial media Fierce Biotech, last year, the top 10 global pharmaceutical companies in terms of major business revenue cut a total of more than 50 drug development pipelines while global biopharmaceutical investment began to slow in 2022 after experiencing two years of fairly high levels during the COVID-19 pandemic.
据美国工业媒体Fierce Biotech报道，去年，全球主要业务收入排名前十的制药公司削减了总共50多条药物开发管道，而全球生物制药投资在新冠肺炎大流行期间经历了两年的高水平后，于2022年开始放缓。
Moderna has already registered a biotech company in Minhang district and established its Chinese headquarters there.
莫德纳已经在闵行区注册了一家生物技术公司，并在那里设立了中国总部。
Moderna has registered a biotech company branch in Minhang District and established its Chinese headquarters there.
莫德纳公司在闵行区注册了一家生物技术公司分公司，并在那里设立了中国总部。
Danish biotech firm sees potential in nation's efforts toward carbon goalsDanish biological products provider Novozymes is eager to capture opportunities in China by intensifying its focus on innovation and offering localized biotech solutions, the company said.
丹麦生物技术公司看到了国家实现碳目标的潜力。该公司表示，丹麦生物产品供应商诺维信渴望通过加强对创新的关注和提供本地化的生物技术解决方案来抓住中国的机遇。
"As a biotech powerhouse, Novozymes will continue to leverage our expertise in low-carbon technologies to help more Chinese customers achieve their sustainability objectives," said Fano, who was in the country recently to attend the 15th China Bioindustry Convention in Wuhan, Hubei province.
法诺说：“作为一家生物技术巨头，诺维信将继续利用我们在低碳技术方面的专业知识，帮助更多的中国客户实现可持续发展目标。
Biotech will play a critical role in reusing organic waste through waste-to-energy applications, including agricultural waste (biomass), waste oil and fats.
生物技术将通过废物转化为能源的应用，在有机废物的再利用方面发挥关键作用，包括农业废物（生物质）、废油脂。
We see a great potential for developing biotech solutions to fulfill the needs of more clients and partners in China," she added.
我们看到开发生物技术解决方案的巨大潜力，以满足中国更多客户和合作伙伴的需求，”她补充道。
The company has also established strategic partnerships with various China-based biotech and tech companies such as Innovent Biologic, Insilico Medicine, Adagene and Baidu, to accelerate its pace in fields including oncology, AI drug discovery and antibody development technology.
该公司还与Innovent Biologic、Insilico Medicine、Adagene和百度等多家中国生物技术公司建立了战略合作伙伴关系，以加快其在肿瘤学、人工智能药物发现和抗体开发技术等领域的步伐。
Shi also said the company will further cooperate with local enterprises in fields ranging from innovative medicine, biopharmaceutical, biotech, and technology and digitalization, to drive its development in China.
施还表示，该公司将进一步与当地企业在创新医学、生物制药、生物技术、技术和数字化等领域进行合作，以推动其在中国的发展。
Through the upgraded AstraZeneca's Global R&D China Center, which was unveiled in Shanghai in October 2021, a rising number of biotech innovations are being promoted to contribute to global development, said a senior executive of the United Kingdom-based pharmaceutical company.
这家总部位于英国的制药公司的一位高管表示，通过2021年10月在上海揭幕的升级版阿斯利康全球研发中国中心，正在推动越来越多的生物技术创新，为全球发展做出贡献。
Another example is that the company has recently entered into cooperation with local biotech enterprise Harbour BioMed on the development and commercialization of an innovative immune cell engager that may benefit gastric cancer patients, she said.
她说，另一个例子是，该公司最近与当地生物技术企业Harbour BioMed就一种创新的免疫细胞接合器的开发和商业化进行了合作，这种接合器可能有益于癌症患者。
Opportunities for results derived from China are rising, especially due to the country's accelerated developing ecosystem in biopharmaceutical development, allowing the market to become an important source of innovation, said Galbraith, who was scheduled to meet with biotech enterprises and academic and medical institutions during her visit.
Galbraith说，从中国获得成果的机会正在增加，特别是由于该国生物制药开发生态系统的加速发展，使市场成为创新的重要来源。她计划在访问期间会见生物技术企业、学术和医疗机构。
China's ecosystem of biotech and entrepreneurs is growing and so is its capability and experience, said Galbraith.
Galbraith说，中国的生物技术和企业家生态系统正在发展，其能力和经验也在增长。
The company sees biotech as a catalyst for China's sustainable transformation and it will continue to expand investments in the country.
该公司将生物技术视为中国可持续转型的催化剂，并将继续扩大在中国的投资。
China's pharmaceutical conglomerate Sino Biopharmaceutical Limited, or Sino Biopharm, announced on Thursday the acquisition of Nasdaq-listed United Kingdom based biotech F-star Therapeutics, marking a latest move in Sino Biopharm's on-going global growth.
周四，中国制药集团Sino Biopharmaceutical Limited（简称Sino Biocharm）宣布收购在纳斯达克上市的英国生物技术公司F-star Therapeutics，这标志着Sino Bioharm持续全球增长的最新举措。
She also said that leveraging on Sino Biopharm's innovative medicine development and commercialization platforms, the company will continue to actively cooperate with multinational pharmaceutical companies and overseas biotech enterprises, with an open, equal and mutually beneficial attitude, to better meet unfulfilled clinical needs.
她还表示，公司将继续以开放、平等、互利的态度，利用Sino Biopharm的创新药物开发和商业化平台，积极与跨国制药公司和海外生物技术企业合作，更好地满足尚未满足的临床需求。
Taking China as a key source of global innovation, he said that the team at Collaborate to Cure Hub China is dedicated to sourcing innovation in the local ecosystem to explore new ways to partner with universities, research institutes and biotech companies, for delivering breakthrough innovations for patients, today and in the future.
他将中国视为全球创新的关键来源，他表示，中国合作治疗中心的团队致力于在当地生态系统中寻找创新，探索与大学、研究机构和生物技术公司合作的新方式，为患者提供突破性创新，无论是现在还是未来。
Hangzhou, Zhejiang province-based cancer screening biotech company New Horizon Health has put into operation an international research and development center in Hong Kong as part of its stepped-up efforts to increase its presence in global markets.
总部位于浙江省杭州市的癌症筛查生物技术公司New Horizon Health在香港设立了一个国际研发中心，这是其为增加其在全球市场的影响力而加紧努力的一部分。
With rapid development and a promising future, cosmetic companies are stepping into China's biotech industry.
随着快速的发展和充满希望的未来，化妆品公司正在进军中国的生物技术行业。
In 2022, Hangzhou-based cosmetics company Proya invested in Shenzhen, Guangdong province-based Siyomicro Bio-Tech Co Ltd. Later on, it signed a strategic partnership with Zhejiang Peptites Biotech Co Ltd, working on innovative peptide research and development, peptide green synthesis, and raw material production and supply, demonstrating its latest efforts in using synthetic biology to reconstruct the upstream raw materials of the medical aesthetics industry.
2022年，总部位于杭州的化妆品公司Proya投资了总部位于广东省深圳市的四微生物技术有限公司。随后，该公司与浙江百事生物技术有限责任公司签署了战略合作伙伴关系，致力于创新肽研发、肽绿色合成和原料生产供应，展示了其在利用合成生物学重建医美产业上游原材料方面的最新努力。
"More and more cosmetics giants are entering the biotech industry as venture capitalists, gradually shaping the application of biotech in the medical aesthetics industry.
“越来越多的化妆品巨头以风险投资家的身份进入生物技术行业，逐渐塑造生物技术在医美行业的应用。
Ideally, they hope to create a hyaluronic acid-like best-selling product in the next decade," said Zhao Hongwei, a biotech analyst at VBData.
理想情况下，他们希望在未来十年内创造出类似透明质酸的畅销产品，”VBData生物技术分析师赵宏伟说。
The two major bestsellers in China's biotech industry are hyaluronic acid and collagen.
中国生物技术行业最畅销的两款产品是透明质酸和胶原蛋白。
"The burgeoning of the sector offered a foundation for cosmetics companies such as Proya and Shiseido to enter the biotech industry, as currently, the production technology is mature and cosmetics companies do not need to spend a great deal of money to purchase listed companies to acquire the technology," Zhao said.
赵说：“该行业的蓬勃发展为Proya和资生堂等化妆品公司进入生物技术行业奠定了基础，因为目前生产技术已经成熟，化妆品公司不需要花大量资金购买上市公司来获得技术。”。
Yuan Shuai, deputy head of the Rural Revitalization Committee, a research institute, said: "In recent years, basic research and applied research in the biotech industry in China experienced rapid development, new technologies emerged and the biotech industry has become an important driving force for the world economy.
研究机构乡村振兴委员会副主任袁帅表示：“近年来，中国生物技术产业的基础研究和应用研究快速发展，新技术不断涌现，生物技术产业已成为世界经济的重要驱动力。
"The country's 14th Five-Year Plan (2021-25) includes measures to accelerate the application of biotech in healthcare, agriculture, energy and environmental protection, providing policy support for the development of the industry.
“国家的第十四个五年计划（2021-25年）包括加快生物技术在医疗保健、农业、能源和环境保护中的应用的措施，为该行业的发展提供政策支持。
"To develop China's biotech industry, more efforts are needed in enhancing innovation capability, accumulating scientific theoretical foundation, developing high-end equipment and gathering bio-information resources.
“发展中国的生物技术产业，需要在增强创新能力、积累科学理论基础、开发高端设备和收集生物信息资源等方面做出更多努力。
LePure Biotech Co Ltd, a leading Chinese bioprocessing company, announced on Thursday the completion of Series C financing co-led by Novo Holdings, General Atlantic and Goldman Sachs Asset Management.
中国领先的生物加工公司乐纯生物技术有限公司周四宣布完成由Novo Holdings、General Atlantic和高盛资产管理公司共同牵头的C轮融资。
Sean He, partner and head of Novo Holdings China, said that he is excited to work closely with LePure Biotech, making it one of Novo Holdings' flagship achievements in China.
诺沃控股中国区合伙人兼负责人何表示，他很高兴能与乐纯生物紧密合作，使其成为诺沃控股在中国的旗舰成就之一。
In an interview with China Daily, Wang Feng, co-founder and CEO of LePure Biotech, said that Chinese local bioprocessing companies are rapidly increasing their R&D and manufacturing capabilities.
乐纯生物联合创始人兼首席执行官王峰在接受《中国日报》采访时表示，中国本土生物加工公司正在迅速提高研发和制造能力。
LePure Biotech has already set up overseas sites and research facilities, including a research and development center in Boston, United States.
乐纯生物已经在海外建立了工厂和研究设施，包括位于美国波士顿的研发中心。
China is also expected to continue to move up on the technology and quality front, therefore domestic players such as LePure Biotech will play a pivotal role in both the innovation and supply chain in China and then globally.
预计中国也将继续在技术和质量方面取得进展，因此，乐纯生物等国内企业将在中国乃至全球的创新和供应链中发挥关键作用。
Kakar also believes strategic M&As as well as continuous innovation are important in driving LePure Biotech's future growth.
Kakar还认为，战略并购和持续创新对推动乐纯生物未来的增长至关重要。
We are very excited to see a new generation of innovative biotech companies in China," he added.
我们很高兴看到中国新一代的创新生物技术公司，”他补充道。
Apart from serving 300 leading corporates, Citi banks on a far greater number of "emerging" companies, across biotech, fintech and other new economy sectors.
除了为300家领先企业提供服务外，花旗还为生物技术、金融科技和其他新经济部门的更多“新兴”公司提供银行服务。
Located in Shanghai, the facility is aimed at catering to the fast-growing demands for biotech solutions from the world's most populous market.
该工厂位于上海，旨在满足世界上人口最多的市场对生物技术解决方案的快速增长需求。
These cheetahs come from 30 Chinese cities, mainly in Shanghai (54 cheetahs), Beijing (49 cheetahs), Shenzhen (30 cheetahs), as well as Hangzhou (30 cheetahs), that are engaged in biotech, healthtech, enterprise services and e-commerce industries.
这些猎豹来自中国30个城市，主要分布在上海（54只）、北京（49只）、深圳（30只）和杭州（30只猎豹），从事生物技术、健康科技、企业服务和电子商务行业。
Zhu Jingjin, vice-president of China National Biotec Group－Sinopharm's biotech subsidiary－said three virus antibody drugs for COVID-19 have all entered clinical trials with steady progress.
中国国药集团生物技术子公司中国生物技术集团副总裁朱晶晶表示，三种治疗新冠肺炎的病毒抗体药物均已进入临床试验，并取得稳步进展。
Zhu Jingjin, deputy president of China National Biotec Group, China National Pharmaceutical Group's biotech subsidiary, said at a media conference in Beijing on Monday the company's three virus neutralizing antibody drugs for treating COVID-19 have all entered clinical trials and are showing steady progress.
中国医药集团旗下生物技术子公司中国生物技术集团副总裁朱晶晶周一在北京举行的媒体会议上表示，该公司用于治疗新冠肺炎的三种病毒中和抗体药物均已进入临床试验，并显示出稳步进展。
Sinovac Biotech's COVID-19 vaccine called CoronaVac has been approved for children aged six months to three years in Hong Kong from Thursday, the Beijing-based biopharmaceutical product provider said on Wednesday.
总部位于北京的生物制药产品提供商科兴生物周三表示，该公司的新冠肺炎疫苗CoronaVac已于周四在香港获准用于6个月至3岁的儿童。
So far, three Chinese COVID-19 vaccines, manufactured by China National Biotec Group, Sinovac Biotech Ltd and CanSino Biologics Inc, have won emergency use approval from the World Health Organization.
到目前为止，由中国生物技术集团、科兴生物技术有限公司和康希诺生物制品公司生产的三种中国新冠肺炎疫苗已获得世界卫生组织的紧急使用批准。
Sinovac Biotech Ltd, a biopharmaceutical product provider in China, officially unveiled a vaccine quality research center in Changping district of Beijing on Sunday.
周日，中国生物制药产品供应商科兴生物技术有限公司在北京昌平区正式启用了一个疫苗质量研究中心。
Sinovac Biotech Ltd, a biopharmaceutical product provider in China, announced on Tuesday that a phase-3 clinical trial for its inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile.
中国生物制药产品供应商科兴生物技术有限公司周二宣布，其四价流感灭活疫苗的三期临床试验已在智利共和国启动。
Chinese vaccine producer Sinovac Biotech officially kicked off a clinical trial in Hong Kong on Monday to assess the safety and immunogenicity of its Omicron-specific COVID-19 inactivated vaccine which will be used as a booster shot in healthy adults.
中国疫苗生产商科兴生物周一在香港正式启动临床试验，以评估其奥密克戎特异性新冠肺炎灭活疫苗的安全性和免疫原性，该疫苗将用于健康成年人的加强针。
Sansure Biotech, a Changsha, Hunan province-based in-vitro diagnostic (IVD) product producer specializing in molecular diagnostics and genetic testing, is among those enjoying revenue spikes and technological upgrades amid surging demand for COVID-19 test kits.
在新冠肺炎检测试剂盒需求激增的情况下，专注于分子诊断和基因检测的湖南长沙体外诊断（IVD）产品生产商Sansure Biotech是收入激增和技术升级的公司之一。
On May 24, it announced that a nucleic acid test kit for detecting hepatitis B, hepatitis C and HIV developed by Sanway Gene, its wholly owned subsidiary, had received certification from a European Union Notified Body, marking the fourth Conformite Europeenne (CE) certification obtained by Sansure Biotech for List A products following the certification of three other products on May 20.
5月24日，该公司宣布，其全资子公司三威基因开发的一种用于检测乙型肝炎、丙型肝炎和艾滋病毒的核酸检测试剂盒已获得欧盟公告机构的认证，这标志着继5月20日其他三种产品获得认证后，三威生物技术公司第四次获得a级产品的符合欧洲标准（CE）认证。
"The certification will enable us to compete against global players in the mainstream international markets of molecular diagnostic solutions," said Dai Lizhong, chairman of Sansure Biotech.
“该认证将使我们能够在分子诊断解决方案的主流国际市场上与全球参与者竞争，”三苏生物技术董事长戴立忠说。
Sansure Biotech, part of the increasingly impressive domestic IVD enterprise fleet, said it has strengthened research and development investment into a myriad of technologies and platforms.
Sansure Biotech是越来越令人印象深刻的国内IVD企业团队的一部分，它表示已经加强了对无数技术和平台的研发投资。
Chinese biotech enterprise BeiGene announced on Monday that its cancer treatment Brukinsa (zanubrutinib) has been approved by authorities in Kuwait, Bahrain and Qatar for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
中国生物技术企业百济基因周一宣布，其癌症治疗药物Brukinsa（zanubrutinib）已获得科威特、巴林和卡塔尔当局的批准，用于治疗至少接受过一次治疗的成年套细胞淋巴瘤患者。
BeiGene said it is working with NewBridge Pharmaceuticals, a local specialty company that has partnerships with global pharma and biotech companies, to bring the drug to patients in Kuwait, Bahrain, Qatar, Saudi Arabia, United Arab Emirates and other markets in the Middle East and North Africa region following regulatory approval.
百济基因表示，在监管部门批准后，它正在与当地的一家与全球制药和生物技术公司有合作关系的专业公司NewBridge Pharmaceuticals合作，将该药物带给科威特、巴林、卡塔尔、沙特阿拉伯、阿拉伯联合酋长国以及中东和北非地区其他市场的患者。
Hangzhou, Zhejiang province-based cancer screening biotech company New Horizon Health announced a strategic partnership on Monday with Hong Kong-based Prenetics Group Ltd to launch its ColoClear, a non-invasive stool-based test for colorectal cancer, in Hong Kong as a first step to venture in markets beyond the Chinese mainland.
浙江省杭州市癌症筛查生物技术公司New Horizon Health周一宣布与香港Prenetics Group Ltd建立战略合作伙伴关系，在香港推出ColoClear，这是一种针对癌症的非侵入性粪便检测，是进军中国大陆以外市场的第一步。
As synthetic biology is expected to embrace massive opportunities in China, Cathay Biotech, a listed company engaged in the research, development, production and sales of new bio-based materials, plans to further tap the sector.
随着合成生物学有望在中国抓住巨大机遇，从事新型生物材料研发、生产和销售的上市公司国泰生物计划进一步挖掘该行业。
"Through the use of synthetic biology, Cathay Biotech makes it possible for the drastic reduction of carbon emissions of its products, with advantages in terms of both performance and economics.
“通过使用合成生物学，国泰生物技术使其产品的碳排放大幅减少成为可能，在性能和经济性方面都具有优势。
With the polyamide industry being its major business, Cathay Biotech currently produces monomer raw materials that can be used in the production of bio-based polyamides, which can be applied in many fields including textiles, automobiles, electronic appliances, consumer goods and other fields.
国泰生物以聚酰胺行业为主要业务，目前生产可用于生产生物基聚酰胺的单体原料，可应用于纺织、汽车、电子电器、消费品等多个领域。
Cathay Biotech has been working together with the Shanxi provincial government to promote low-carbon development and produce biomaterials for a wide range of products, including automotive materials, wind turbine blades, shipping containers as well as textiles from agricultural products and waste.
国泰生物一直与山西省政府合作，促进低碳发展，生产各种产品的生物材料，包括汽车材料、风力涡轮机叶片、船运集装箱以及农产品和废物纺织品。
"Unlike most synthetic materials made from petroleum, we make similar products from plants, as bio-based polyamides－the basic raw material used to produce a variety of products－are extracted from corn and the stalks of other crops," said Zang Huiqing, vice-president of Cathay Biotech.
国泰生物科技副总裁臧惠清表示：“与大多数由石油制成的合成材料不同，我们从植物中生产类似的产品，因为用于生产各种产品的基本原料生物基聚酰胺是从玉米和其他作物的秸秆中提取的。”。
One of Cathay Biotech's largest production facilities in China is Shanxi Synthetic Biological Industry Park.
国泰生物在中国最大的生产设施之一是山西合成生物产业园。
When talking about Cathay Biotech's dream of expansion, Liu said the company hopes to develop a bio-based materials industry as big as petrochemicals.
在谈到国泰生物的扩张梦想时，刘表示，该公司希望发展一个与石化产品一样大的生物材料行业。
The company has been creating a large number of solutions and patents in the sector in recent years, including bio-manufactured long-chain diacids, of which Cathay Biotech is a leading supplier worldwide already, thanks to its years of research and development investment.
近年来，该公司在该行业创造了大量解决方案和专利，包括生物制造的长链二酸，由于其多年的研发投资，国泰生物技术已经成为全球领先的供应商。
"Cathay Biotech will continue to promote the innovation of bio-based products and technologies based on our core technologies, and to provide a positive force for the development of synthetic biology and bio-manufacturing to lead the sustainable development of technologies and industries," he said.
他说：“国泰生物将继续以我们的核心技术为基础，推动生物制品和技术的创新，为合成生物学和生物制造业的发展提供积极的力量，引领技术和产业的可持续发展。”。
Its technology and products are widely applied in various industries like wastewater treatment, biotech, pharmaceuticals, plant chemical extraction and food processing.
其技术和产品广泛应用于废水处理、生物技术、制药、植物化学提取和食品加工等各个行业。
Biotech company MGI Tech delivered a container laboratory to Laos on Thursday, so as to help the country boost its mass COVID-19 testing capacity and prepare for the gradual re-opening of its borders in 2022.
生物技术公司MGI Tech周四向老挝交付了一个集装箱实验室，以帮助该国提高其大规模新冠肺炎检测能力，并为2022年逐步重新开放边境做好准备。
The medicine was a potentially best-in-class innovative tumor drug developed by Nanjing-based Legend Biotech.
该药物是南京传奇生物技术有限公司开发的一种潜在的同类最佳创新肿瘤药物。
Novotech Health Holdings, a leading biotech company, announced it has raised a total of $760 million in its latest financing round, which will drive the company in pursuing further growth opportunities.
领先的生物技术公司Novotech Health Holdings宣布，其在最新一轮融资中共筹集了7.6亿美元，这将推动该公司寻求进一步的增长机会。
"We look forward to accelerating our growth by pursuing various strategic M&A and tech enablement initiatives and seek to better serve our biotech and pharmaceutical clients and support the clinical research industry in the development of a wide spectrum of therapeutic areas," Novotech CEO John Moller said.
Novotech首席执行官John Moller表示：“我们期待着通过实施各种战略并购和技术支持举措来加快我们的增长，并寻求更好地服务于我们的生物技术和制药客户，支持临床研究行业开发广泛的治疗领域。”。
Clover Biopharmaceuticals Ltd, a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced on Wednesday the construction of a new research and development center in Zhangjiang Biotech and Pharmaceutical Industrial Base in Shanghai.
三叶草生物制药有限公司，一家开发新型疫苗和候选生物治疗药物的全球临床生物技术公司，周三宣布在上海张江生物技术和制药工业基地建设一个新的研发中心。
The Zhangjiang Biotech and Pharmaceutical Industrial Base, dubbed "Zhangjiang Pharma Valley", is one of the top biotech hubs in China and is home to over 1,000 innovative biotechnology and biopharmaceutical companies.
张江生物医药产业基地被称为“张江制药谷”，是中国顶尖的生物技术中心之一，拥有1000多家创新生物技术和生物制药公司。
"The center is focused on cultivating entrepreneurship for new biotech companies with a passion for transformational medicines, diagnostics and medical devices that can help address unmet needs, and advancing breakthrough innovations from early discovery to being accessed by patients all over the world," he said.
他说：“该中心专注于为新的生物技术公司培养创业精神，这些公司对转型药物、诊断和医疗设备充满热情，可以帮助解决未满足的需求，并推动突破性创新，从早期发现到全世界的患者都能获得。”。
Boehringer Ingelheim announced a partnership with Shanghai ZJ Biotech Co Ltd during the fourth China International Import Expo in early November.
勃林格殷格翰在11月初举行的第四届中国国际进口博览会上宣布与上海ZJ生物技术有限公司建立合作关系。
It served as a latest example of how the model of contract development manufacturing organization, or CDMO, may help domestic biotech startups develop and commercialize products while maximizing their value.
它是合同开发制造组织模式（CDMO）如何帮助国内生物技术初创公司开发和商业化产品，同时实现其价值最大化的最新例子。
They are willing to spend on healthcare products and services, and this trend would significantly benefit Danaher's life sciences, biotech and diagnostics businesses in China for the long run, said Shen Yi, the group's vice-president and head of mergers and acquisitions for Asia.
该集团副总裁兼亚洲并购主管沈毅表示，他们愿意在医疗保健产品和服务上花钱，从长远来看，这一趋势将大大有利于达那和在中国的生命科学、生物技术和诊断业务。
With its advantages in world-class medical science, IT and health services; its position as the second-biggest biotech fundraising hub in the world; as well as new policies to foster scientific exchange and health innovation; GBA brings AstraZeneca great opportunities to leverage our global resources and strong innovative power to build an ecosystem of collaboration and foster a new wave of world-class developments to benefit the healthcare industry and patients around the world.
凭借其在世界级医学、IT和健康服务方面的优势；其作为世界第二大生物技术筹资中心的地位；以及促进科学交流和卫生创新的新政策；GBA为阿斯利康带来了巨大的机会，可以利用我们的全球资源和强大的创新能力，建立合作生态系统，并推动新一轮世界级的发展，造福世界各地的医疗保健行业和患者。
DXY announced in November last year it had teamed up with major vaccine enterprises, such as MSD, GSK, Sinovac Biotech and Hualan Biological Engineering, to establish a vaccination service platform.
丁香园去年11月宣布，已与默沙东、葛兰素史克、科兴生物和华兰生物工程等主要疫苗企业合作，建立疫苗接种服务平台。
Global life sciences company Cytiva and local biotech company Shengsen signed a strategic cooperation memorandum during the expo, vowing to promote the joint pilot production of antibodies during the research and development phase.
全球生命科学公司Cytiva和当地生物技术公司盛森在博览会期间签署了战略合作备忘录，誓言在研发阶段推动抗体的联合中试生产。
Last year, US-based biotech company Illumina inked collaborations valued at more than 10 million yuan ($1.57 million) after it made its CIIE debut.
去年,这家美国生物科技公司因首次参加进博会,促成了价值超过1000万元人民币(157万美元)的合作。
Innovation vitality from home and abroad can be propelled mutually and form positive interaction cycles to provide a steady stream of new drugs, said some multinational biotech companies ahead of the fourth China International Import Expo, which will open this week.
多家跨国生物技术公司表示，在即将于本周开幕的第四届中国国际进口博览会上，国内外的创新活力可以相互推动，形成积极的互动循环，为新药研发提供源源不断的动力。
In a recent development, Apeloa announced it will establish a research and development center in Boston, Massachusetts, in the United States with an investment of $47 million, further consolidating its overseas business strategy in the biotech sector.
最近，Apeloa公司宣布将在美国马萨诸塞州的波士顿建立一个研发中心，投资金额高达4700万美元，这进一步巩固了其在生物技术领域的海外业务战略。
They are BASF, COMIY, Hongbaoli, Huaheng Biotech, INOV, Landsea, Red Avenue, Rokin Logistics, SCIP SITA, Sino Trans, Snow Breweries, Techstorm, Xiangfeng and Xilong Scientific.
这些公司分别是：巴斯夫（BASF）、COMIY、宏宝利（Hongbaoli）、华恒生物科技（Huaheng Biotech）、INOV、朗诗（Landsea）、红大道（Red Avenue）、罗宾物流（Rokin Logistics）、SCIPI SITA、中远物流（Sino Trans）、雪花啤酒（Snow Breweries）、Techstorm、翔丰（Xiangfeng）和西龙科学（Xilong Scientific）。
The new addition of a health exhibition zone for this fair also showed that the country is supporting local biotech companies to go global, Yang said.
杨晓明说,本届高交会上首次设立的健康展专区也表明,国家正在扶持本土生物技术企业走向世界。
Chinese hyaluronic acid enterprises, such as Bloomage Biotech and Fufeng, are stepping up efforts to improve product quality and quantity to meet fast-rising demand both at home and abroad.
中国的透明质酸企业，如华熙生物和阜丰，正在加大力度提高产品质量和产量，以满足国内外快速上升的需求。
Zhao Yan, president of Bloomage Biotech, a leading Chinese hyaluronic acid producer, said the company relies on science and technology to improve product quality and enhance brand image to increase competitiveness and become more capable to deal with uncertainties.
华熙生物董事长赵燕表示，公司依靠科技提升产品品质、塑造品牌形象以增强竞争力，从而有能力应对各种不确定性。作为中国领先的透明质酸（玻尿酸）生产商，华熙生物深知科技创新对于企业长远发展的重要性。通过持续的研发投入和技术创新，公司不断提升产品品质，满足消费者对高品质健康产品的需求。同时，塑造良好的品牌形象，增强消费者信任，是提升市场竞争力的关键。面对市场的不确定性和挑战，华熙生物将坚持科技创新，以更优质的产品和服务，赢得消费者的认可和信赖。
Bloomage Biotech said before the pandemic more than half of its raw material products were sold overseas.
华熙生物称，在疫情前，其超过一半的原材料产品都是销往海外的。
With annual production capacity of 320 tons, Bloomage Biotech accounted for 43 percent of global output last year, selling raw material products to more than 40 countries and regions including the United States, the European Union, South Korea and Japan.
去年，华熙生物年产能达320吨，全球市场占有率达43%，原料产品销往美国、欧盟、韩国、日本等超过40个国家和地区。
Rupert Hoogewerf, chairman and chief researcher for the Hurun Report, said that the total value of the top 500 companies increased over 100 trillion yuan over the period before the COVID-19 pandemic, mainly resulting from the maturity of the digital economy and the booming biotech sectors.
胡润百富董事长兼首席研究员胡润表示，在新冠疫情前，中国500强企业的总价值增长超过100万亿元，这主要是由于数字经济的成熟和生物技术行业的蓬勃发展。
Mei said he believes that the young generation of talent will play a key role in China's rise in the biotech field on the world stage as they are highly open-minded, receptive to new products and ideas, and internationally-oriented.
梅表示，他相信年轻一代人才将在推动中国生物技术领域在世界舞台上崛起中发挥关键作用，因为他们思维高度开放、乐于接受新产品和新思想，并具有国际视野。
US-based IQVIA Biotech, a global provider of advanced analytics and clinical research services, plans to continue to invest in China's biopharmaceutical industry, said a senior executive.
美国艾昆纬生物技术公司(IQVIA Biotech)的一位高级管理人员表示，作为全球先进的分析和临床研究服务提供商，艾昆纬生物技术公司计划继续投资中国的生物制药行业。
Liu Qun, head of IQVIA Biotech China, said: "China is the second-largest and one of the fastest-growing healthcare markets in the world.
刘群，IQVIA Biotech中国区总经理表示：“中国是全球第二大、同时也是增长最快的医疗市场之一。"
On May 25, IQVIA announced its expansion into Japan and the Asia Pacific－a tailored approach to delivering integrated clinical and commercial solutions for biotech and emerging biopharma companies.
5月25日，IQVIA宣布进军日本和亚太地区，为生物技术和新兴生物制药公司提供定制化的综合临床和商业解决方案。这标志着IQVIA在亚洲市场的进一步扩张，旨在通过其专业服务和创新解决方案，支持该地区生物技术和新兴生物制药企业的成长与发展。IQVIA将利用其全球经验和本地洞察，为客户提供从临床研究到市场推广的全方位服务，帮助他们加速药物研发进程，提高市场竞争力。
"Biotech companies are fueling rapid development of biologics, drugs and vaccines, and when they succeed, we all succeed," said Richard Staub, president of research and development solutions at IQVIA.
生物技术公司正在推动生物制剂、药物和疫苗的快速发展，当他们取得成功时，我们所有人都是赢家，"IQVIA研发解决方案总裁Richard Staub表示。
"By launching IQVIA Biotech in JAPAC, we can support the aspirations of biotech customers with agile solutions and resources dedicated to supporting smaller companies," Staub said.
“通过在亚太区推出IQVIA Biotech，我们可以利用灵活的解决方案和专门支持小型企业的资源，来支持生物技术客户的雄心壮志，”Staub说道。这句话的意思是，通过在亚太地区启动IQVIA Biotech项目，他们能够提供更灵活的解决方案和特别为小型生物技术公司服务的资源，从而帮助这些公司的业务发展和实现他们的目标。